S-1: Synergy CHC Corp. Files S-1 for $36M ELOC, Stock Resale

Synergy CHC Corp. filed an S-1 registration statement for the resale of up to 101.71 million shares by Hudson Global Ventures, LLC, and to register shares for a potential $36 million Equity Line of Credit.

Summary

• The company filed an S-1 registration statement for the resale of up to 101,710,000 shares of common stock by Hudson Global Ventures, LLC (the Selling Stockholder).
• These shares include 100,000,000 ELOC Shares, 1,540,000 Warrant Shares, and 170,000 Existing Shares.
• The company will not receive any proceeds from the Selling Stockholder's resale of these shares.
• The company may receive up to $36,000,000 in aggregate gross proceeds under an Equity Line of Credit (ELOC) Purchase Agreement with the Selling Stockholder, which will be used for general corporate purposes and working capital.
• The ELOC Purchase Agreement allows the company to direct the Selling Stockholder to purchase shares over approximately 24 months, with the purchase price based on discounted market prices.
• A warrant to purchase 1,540,000 shares at an exercise price of $0.01 per share was issued to the Selling Stockholder as a commitment fee for the ELOC.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol SNYR, with a last reported sale price of $0.30 per share on May 13, 2026.
• Synergy CHC Corp. is a provider of consumer health care, beauty, and lifestyle products, primarily through its FOCUSfactor (brain health supplement) and Flat Tummy (lifestyle and wellness) brands.
• Products are sold through major retailers like Costco, Amazon.com, Walmart, Walgreens, BJs, and The Vitamin Shoppe, and direct-to-consumer.
• For the year ended December 31, 2025, revenue was $30.4 million, net income was $(12.3) million, and EBITDA was $(6.2) million.
• This compares to the year ended December 31, 2024, where revenue was $34.8 million, net income was $2.1 million, and EBITDA was $6.5 million.
• The 2025 EBITDA decrease was attributed to a $6.7 million bad debt reserve and a $0.9 million inventory write-off.
• The company's working capital improved from a $1.1 million deficit at December 31, 2024, to a $1.8 million surplus at December 31, 2025.
• FOCUSfactor net revenue decreased 10% year-over-year to $27.8 million in 2025, primarily due to rebranding and packaging upgrades, while Flat Tummy's revenue contribution decreased from 12% to 8% of net revenue.
• The company has not historically paid or declared dividends and does not expect to in the future.
• The issuance of common stock under the ELOC may cause substantial dilution to existing stockholders and could lead to a decline in the stock price.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the ELOC provides much-needed capital access and the company has clear growth strategies and strong brands, the significant decline in net income and EBITDA in 2025, coupled with potential dilution from the ELOC, presents considerable headwinds.

Positives

• The company has secured access to up to $36,000,000 in gross proceeds through the ELOC Purchase Agreement, providing crucial capital for working capital and general corporate purposes.
• Working capital improved significantly from a $1.1 million deficit at December 31, 2024, to a $1.8 million surplus at December 31, 2025.
• The company possesses a strong brand portfolio, including FOCUSfactor, a clinically-tested brain health supplement, and Flat Tummy, a lifestyle and wellness brand.
• FOCUSfactor has expanded its product line from 3 SKUs at acquisition to over 34 SKUs, and Flat Tummy from 1 SKU to 13 SKUs, demonstrating successful product development.
• Successful pilot programs for FOCUSfactor Ready-To-Drink (RTD) products in Texas (sales ranging from $550 to $2,382 per club per week) and Canada (sales ranging from C$378 to C$2,206 per club per week) indicate market acceptance and growth potential.
• An asset-light business model, relying on third-party manufacturers, allows for quick and profitable scaling to meet growing demand.
• The company is well-positioned in growing market categories, with the brain health segment projected to grow at an 8% CAGR in the U.S. and 13% globally through 2030.
• An experienced management team with a proven track record of acquiring brands at attractive valuations, such as FOCUSfactor at approximately 3x trailing EBITDA.
• Established premier retail partnerships with major players like Costco, Amazon.com, Walmart, Walgreens, BJs, and The Vitamin Shoppe provide a strong distribution platform.
• Strategic growth initiatives include broadening media advertising, acquiring complementary brands, expanding retail partnerships, diversifying geographic presence, and boosting consumer engagement through innovative strategies.

Negatives

• The company reported a significant net loss of $(12.3) million for the year ended December 31, 2025, a substantial decline from a net income of $2.1 million in the prior year.
• EBITDA decreased sharply from $6.5 million in 2024 to a negative $(6.2) million in 2025.
• Total revenue declined from $34.8 million in 2024 to $30.4 million in 2025.
• FOCUSfactor's net revenue decreased 10% year-over-year in 2025, primarily due to rebranding and packaging upgrades, indicating challenges in maintaining sales during transitions.
• Flat Tummy's contribution to net revenue decreased from 12% in 2024 to 8% in 2025, suggesting a decline in its relative performance.
• The company's capital structure has historically been highly levered, limiting resources for business growth prior to the ELOC agreement.
• The issuance of common stock to the Selling Stockholder under the ELOC Purchase Agreement may cause substantial dilution to existing stockholders.
• Sales of shares by the Selling Stockholder could exert downward pressure on the common stock price.
• The company has not historically paid dividends and does not expect to, meaning investor returns are solely dependent on stock price appreciation.
• The company operates in a highly competitive and fragmented industry with few barriers to entry, facing competitors with significantly greater resources.
• Sales growth is heavily reliant on maintaining relationships with a small number of large customers, posing a risk if any of these relationships are disrupted.
• The company does not currently carry directors and officers insurance, which could expose it to greater financial risk in the event of litigation against management.

Risks

• Operating in a highly competitive industry, where failure to compete effectively could materially and adversely affect sales and growth prospects.
• Failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements could significantly harm customer relationships, product sales, financial condition, and operating results.
• Sales growth is dependent upon maintaining relationships with a small number of existing large customers, and the loss of any one such customer could materially adversely affect the business and financial performance.
• Outside suppliers and manufacturers failing to supply products in sufficient quantities and in a timely fashion could cause the business to suffer.
• Adverse or negative publicity could cause the business to suffer.
• Inability to successfully execute on, or realize the expected benefits from, the implementation of strategic initiatives, and the pursuit of new strategic initiatives may pose significant costs and risks.
• Third parties may assert intellectual property infringement claims against the company.
• Planned expansion into additional international markets will expose the company to significant operational risks.
• The company may experience product recalls, withdrawals, or seizures, which could materially and adversely affect its business, financial condition, and results of operations.
• The company and its suppliers are subject to numerous laws and regulations that apply to the manufacturing and sale of nutritional supplements, and compliance with these laws and regulations may increase costs, limit sales, or subject the company to enforcement action or litigation.
• It is not possible to predict the actual number of shares the company will issue to the Selling Stockholder, leading to uncertainty regarding future dilution.
• Investors who buy shares at different times will likely pay different prices and may experience different levels of dilution and investment outcomes.
• The issuance of common stock to the Selling Stockholder may cause substantial dilution to existing stockholders, and the sale of such shares could cause the price of the common stock to decline.
• The company has not historically paid or declared any dividends on its common stock and does not expect to pay or declare cash dividends in the future on a regular basis, if at all.
• The company is subject to Nevada anti-takeover laws (NRS Sections 78.438, 78.439, 78.378-78.3793) which could delay, defer, or prevent a change of control.

Future Outlook

The company intends to accelerate the growth of both its FOCUSfactor supplements and FOCUSfactor energy Ready To Drink (RTD) products. It plans a coordinated expansion of its advertising strategy during 2026, focusing on pushing additional SKUs within its retail sales partner network and investing in online marketing. The company will continue to evaluate acquisition opportunities that complement its health, beauty, and lifestyle offerings. It seeks to partner with additional leading retailers, particularly food retailers focused on health foods, to expand its distribution footprint. Geographically, the company aims to accelerate sales growth by expanding into new international markets, with plans to enter Taiwan and Asia in 2026 (initially with FOCUSfactor, then Flat Tummy), followed by Australia. The strategy includes developing highly competitive and differentiated products produced in-country for ease of entry. The company also plans to use innovative strategies to boost consumer engagement and continue to develop and expand its current brands by introducing new products and formulations to satisfy various customer segments and needs.

Management Comments

• "Our capital structure following the acquisitions of our key brands in 2015 has been highly levered, and our focus has been on paying our debt and, as a result, we do not have the resources to grow our business."
• "Managements philosophy is to acquire promising brands that fit within our health, beauty and lifestyle offerings, and apply our marketing and distribution strategies to develop brands to their full potential."
• "We believe we are adept at identifying promising opportunities that build out and complement our core brand portfolio."

Industry Context

StockSavvy.ai notes that Synergy CHC Corp. operates within the dynamic and growing consumer health, beauty, and lifestyle product markets, particularly benefiting from increased consumer focus on wellness. The company's flagship FOCUSfactor brand is positioned in the brain health segment, which Grand View Research projects to grow at an 8% CAGR in the U.S. and 13% globally through 2030, indicating a strong tailwind. Its expansion into the functional energy RTD market with FOCUSfactor energy RTD aligns with a significant industry trend, as the U.S. energy RTD category alone reached $19.2 billion in sales in 2023 with a 6.3% CAGR (Euromonitor). This market is evolving towards dual-benefit products (e.g., Celsius, Beyond Raw, C4 Smart Energy, FocusAid) offering features like focus, energy, zero sugar, and low calories, where Synergy CHC aims to differentiate with its established brand heritage. The company's asset-light model and existing relationships with premier retailers could provide a competitive advantage in penetrating these competitive but expanding sectors.

Comparison to Industry Standards

• The global beverage market, valued at $176 billion in 2022 and projected to grow at an 8.6% CAGR through 2030, provides a substantial and expanding market for Synergy CHC's FOCUSfactor RTD products.
• The U.S. energy RTD category, with sales of $19.2 billion in 2023 and a 6.3% CAGR from 2018-2023, demonstrates a robust growth trajectory that FOCUSfactor's new RTD line aims to capture, competing with established players like Red Bull, Monster, Celsius, Bang, Reign, and C4.
• The brain health supplement segment is projected to grow at an 8% CAGR in the U.S. and 13% globally through 2030, according to Grand View Research, indicating a favorable market environment for FOCUSfactor's core product line.
• The acquisition of the FOCUSfactor brand for approximately 3x trailing EBITDA suggests a disciplined approach to M&A, potentially below typical valuations for established consumer brands, which can range from 5x to 15x EBITDA depending on growth and market position.

Corporate Governance

Related Party Transactions

• The company entered into an Equity Purchase Agreement and a Registration Rights Agreement with Hudson Global Ventures, LLC (the Selling Stockholder) on May 8, 2026.
• As consideration for the ELOC Purchase Agreement, the company issued a warrant to Hudson Global Ventures, LLC for the purchase of 1,540,000 shares of common stock at an exercise price of $0.01 per share.
• The company agreed to pay up to $20,000.00 to Hudson Global Ventures, LLC's legal counsel for expenses related to the preparation of the ELOC Purchase Agreement.
• On May 29, 2025, the company satisfied $12,713,858 of debt previously owed to Knight Therapeutics International S.A. through a combination of cash repayment, an early payment discount, and a conversion of $1,500,000 into equity, issuing a pre-funded common stock purchase warrant to Knight.
• On July 7, 2025, the company issued 60,000 shares of common stock to FMW Media Works, LLC in consideration for consulting services provided under an agreement dated April 9, 2025.
• On March 24, 2026, in connection with a second amendment to its term loan credit agreement, the company issued a common stock purchase warrant to Acme Credit Partners Fund I, LP (a lender) to purchase 3,000,000 shares at an exercise price of $0.00001 per share.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the issuance of up to 101,710,000 shares under the ELOC and warrant exercises, which could negatively impact the per-share value. No dividends are expected, making capital appreciation the sole return mechanism. Nevada anti-takeover provisions and preferred stock authorization could limit shareholder influence on corporate control.
• **Creditors**: The potential to raise up to $36,000,000 through the ELOC could improve the company's liquidity and financial stability, potentially enhancing its ability to meet debt obligations, especially given its historically highly levered capital structure.
• **Employees**: No direct impact on employees is explicitly mentioned, but successful execution of growth strategies and improved financial health could lead to job security and potential expansion opportunities.
• **Customers**: The company's strategic focus on product development, brand expansion, and geographic diversification aims to offer a broader range of products and increase accessibility, potentially benefiting customers with more choices and wider availability.
• **Suppliers**: The asset-light business model relies on third-party manufacturers and suppliers. The company's commitment to maintaining multiple relationships and scaling quickly suggests continued and potentially increased engagement with its supply chain partners.

Next Steps

• The company will file a further amendment to the registration statement to specifically state its effective date.
• The Selling Stockholder may, from time to time, offer and sell the registered shares after the registration statement becomes effective.
• The company may, in its discretion, elect to sell shares of common stock to the Selling Stockholder under the ELOC Purchase Agreement over approximately 24 months.
• Anticipate a coordinated expansion of the advertising strategy during 2026 to build brand awareness and increase reach for FOCUSfactor.
• Continue to invest in online marketing, including social media and influencer-driven marketing, for all brands.
• Evaluate acquisition opportunities that complement the existing brand portfolio in health, beauty, and lifestyle segments.
• Partner with additional leading retailers, including food retailers focused on health foods, to expand the distribution footprint.
• Accelerate sales growth by diversifying geographic presence, with plans to enter Taiwan and Asia in 2026 (initially with FOCUSfactor, then Flat Tummy), followed by Australia.
• Develop highly competitive and differentiated products produced in-country for new international markets, supported by regulatory groups and consultants.
• Initiate retailer meetings in new international markets to gain distribution.
• Further develop and expand current brands by introducing new products, formulations, and alternative delivery formats to satisfy various customer segments and needs.

Key Dates

Recommendation

The company is securing a significant capital facility through an Equity Line of Credit, which is crucial given its historically highly levered capital structure and lack of resources for growth. The strategic focus on expanding core brands, diversifying geographically, and enhancing marketing efforts in growing markets like brain health and functional beverages presents long-term potential. However, the substantial decline in net income and EBITDA in 2025, coupled with the significant potential for dilution from the ELOC shares, introduces considerable risk. A seasoned investor would likely monitor the company's ability to execute its growth strategy, improve profitability, and manage the dilutive impact of the ELOC before making a more aggressive investment decision.

Keywords

Synergy CHC Corp, SNYR, SEC S-1, Equity Line of Credit, ELOC, Common Stock Resale, Nutraceuticals, FOCUSfactor, Flat Tummy, Brain Health Supplement, Wellness Products, Consumer Health, Nasdaq Capital Market, Dilution, Capital Raise, Hudson Global Ventures, Dietary Supplements, Functional Beverages